Stuttgart - Delayed Quote • EUR Coloplast A/S (CBHD.SG) Follow Compare 109.45 +0.25 +(0.23%) As of 8:22:28 AM GMT+1. Market Open. Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for CBHD.SG 1D 5D 2.63% 1M 2.58% 3M -10.03% 6M -7.52% YTD 3.21% 1Y 4.84% 5Y -4.95% All 836.75% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: CBHD.SG View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference call on 4 February 2025 at 11.00am CET (correction) Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference call on 4 February 2025 at 11.00am CET Coloplast A/S - Decisions at the Annual General Meeting 2024 Coloplast divests core Skin Care product portfolio Kerecis included on the list of covered products for Diabetic Foot Ulcers in the final LCD policy Coloplast A/S - Notice of Annual General Meeting 2024 Coloplast AS (CLPBF) Q4 2024 Earnings Call Highlights: Strong Organic Growth and Strategic ... Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24 Coloplast A/S - Full-Year Financial Results 2023/24 Coloplast A/S - Announcement no. 05/2024 - Coloplast expands Executive Leadership Team Stocks to watch this week: Berkshire Hathaway, Super Micro, Novo Nordisk, Vistry and M&S